$1.08
0.065.88%
Last update: Nov 10, 4:27 AM
Lineage Cell Therapeutics Inc
LCTXAMEX
The average analyst price target for Lineage Cell Therapeutics is $5.43, 422.1% above the current price. Of 7 analysts, 7 rate it Buy. Targets range from $3 to $9. The latest change came on Apr 28, 2026, when Canaccord Genuity initiated coverage of Lineage Cell Therapeutics with a Buy rating and a $9 price target.
Price Target Range — 11 Quarters
Analyst Consensus — 7 Analysts
Rating Trend — Last 9 Months
